SRES-104-119
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S1434; text: CR S1433)
Sponsored by John Barrasso (R-WY)
What it does
This resolution officially designates February 27, 2025, as "Rare Disease Day" in the United States. It is a simple commemorative measure passed by the Senate through unanimous consent. It does not create any new law, allocate any funding, or establish any new government program or requirement.
Who benefits
Patients living with rare diseases (estimated 30 million Americans), their families, and caregivers may benefit from increased public visibility for their conditions. Rare disease advocacy organizations and patient groups may gain a platform to raise awareness. Researchers and medical professionals working in the rare disease field may benefit from heightened public attention to their work.
Who is hurt
No specific group is directly or materially harmed by this resolution. It carries no regulatory, financial, or legal obligations for any individual, business, or government entity.
Supporters argue
Supporters argue that designating a national Rare Disease Day draws critical public attention to the approximately 7,000 known rare diseases, most of which lack approved treatments. They contend that awareness days can spur patient advocacy, encourage research funding conversations, and help patients and families feel recognized by their government. Because the resolution passed by unanimous consent, it reflects broad bipartisan agreement that rare disease awareness is a worthy national priority. Supporters also note that this designation aligns the U.S. with an internationally recognized Rare Disease Day observed in dozens of countries, strengthening global coordination on research and patient support.
Opponents argue
Opponents might argue that symbolic resolutions like this one consume limited legislative time and floor resources without producing any concrete, enforceable benefit for rare disease patients. They could contend that a designation alone does nothing to increase research funding, accelerate drug approvals, or reduce the financial burden on patients and families — the tangible changes that would meaningfully improve lives. Critics might further suggest that the Senate's energy would be better directed toward substantive legislation, such as expanding orphan drug incentives or increasing NIH funding, rather than passing commemorative measures that carry no legal or budgetary weight.